Netherlands· NL-c15ec134cd49
Eslibon 600 mg tabletten
A eslicarbazepine product containing eslicarbazepineacetaat, registered in Netherlands by G.L. Pharma GmbH. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Eslicarbazepine is registered in 16 of 19 countries.
Countries holding a registration under ATC N03AF04 (eslicarbazepine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Eslicarbazepine · ATC N03AF04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of eslicarbazepine costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), the median price runs from $2.32 in Italy to $4.08 in Switzerland — a ×1.8 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Eslicarbazepine · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$4.08
- ES Spain$3.49
- IT Italy$2.32
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ESLICARBAZEPINEACETAAT
- Manufacturer
- G.L. Pharma GmbH
- Country
- Netherlands (NL)
- ATC code
- N03AF04
- ATC class
- Eslicarbazepine
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id121341
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
188 interactions on record for eslicarbazepine.
Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eslicarbazepine · interactions on record
188 records
- 17 severe
- 166 moderate
- 5 minor
Most severe, free to view
- Levonorgestrel and ethinylestradiolG03AA07severe
- Desogestrel and ethinylestradiolG03AA09severe
- Drospirenone and ethinylestradiolG03AA12severe
- EthinylestradiolG03CA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Eslicarbazepine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAptiomSumitomo Pharma America, Inc.
- CzechiaZEBINIXBIAL - Portela & Ca., SA, S. Mamede do Coronado
- SpainBIXCAR 600 MG COMPRIMIDOS EFGLaboratorios Alter S.A.
- PolandEslibonG.L. Pharma GmbH
- SwedenZebinix 600 mg TablettBIAL - Portela & CA S.A.
- IcelandZebinixBial - Portela & C. S.A.
- FinlandZebinixBial Portela & C, S.A.
- IrelandZebinix 600 mg TabletBIAL-Portela & Ca, S.A.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Eslibon
- Bulgaria · Еслибон
- Cyprus · Esran
- Czechia · Eslibon, Eslikarbazepin Neuraxpharm
- Germany · Eslibon, Eslicarbazepin Al
- Denmark · Arupsan, Eslicarbazepinacetat "stada"
- Spain · Arupsan, Bixcar
- France · Eslicarbazepine 800, Eslicarbazepine Arrow
- United Kingdom (Northern Ireland) · Arupsan, Eslicarbazepine Amarox
- Greece · Esran
- Hungary · Eslicarbazepine 800
- Iceland · Eslicarbazepin, Eslicarbazepine Acetate Stada
- Italy · Arupsan, Eslicarbazepina Acetato Aurobindo
- Liechtenstein · Zebinix
- Malta · Esran
- Norway · Zebinix
- Poland · Eslibon
- Portugal · Acetato De Eslicarbazepina Alter, Acetato De Eslicarbazepina Aristo
- Sweden · Arupsan
- Slovakia · Eslibon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae3ce2dd-a3fc-4d0f-bf76-ee9b447d4246 GET /v1/drugs/ae3ce2dd-a3fc-4d0f-bf76-ee9b447d4246?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h121341_smpc.pdf",
"strength": null,
"atc_label": "Eslicarbazepine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg121341",
"excipients": [
"CROSCARMELLOSE NATRIUM (E 468)",
"MAGNESIUMSTEARAAT (E 470b)",
"POVIDON K 30 (E 1201)"
],
"substances": [
"ESLICARBAZEPINEACETAAT"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h121341.pdf",
"authorised_at": "2018/08/10",
"procedure_number": "NL/H/4090/003",
"dispensing_status": "Uitsluitend recept",
"registration_number": "121341",
"additional_monitoring": "N"
}See everything about eslicarbazepine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.